Skip to main
RVMD

Revolution Medicines (RVMD) Stock Forecast & Price Target

Revolution Medicines (RVMD) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 55%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Revolution Medicines is a clinical-stage precision oncology company with a promising pipeline of RAS(ON) Inhibitors and a successful track record in structure-based drug discovery. With a high probability of approval for key pipeline candidates and a discounted cash flow valuation methodology, the stock appears undervalued compared to peers in similar stages of development. Risks include clinical setbacks, competition, and dilutive financing, but the potential for long-term market leadership and appreciation in share price make Revolution Medicines an attractive investment opportunity.

Bears say

Revolution Medicines is a clinical stage pharmaceutical company with a heavy focus on developing therapies for RAS-addicted cancers. While they possess unique technologies and capabilities, their near-term revenue forecast is conservative, and their recent combo data does not provide enough justification for their current valuation. Additionally, there is still a significant degree of uncertainty surrounding the success of their ongoing Phase 3 trials. Overall, the low short-term potential for significant revenue growth and high risk in their current pipeline make us wary of investing at this time.

Revolution Medicines (RVMD) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 55% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Revolution Medicines and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Revolution Medicines (RVMD) Forecast

Analysts have given Revolution Medicines (RVMD) a Buy based on their latest research and market trends.

According to 20 analysts, Revolution Medicines (RVMD) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $168.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $168.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Revolution Medicines (RVMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.